引用次数
引用: 97,128
H-指数: 136
I10-指数 : 357
出版物: 680
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan , Ronglai Shen , Daphne C. Ang , Melissa L. Johnson
Clinical Cancer Research 18 ( 22) 6169 -6177
551
2012
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila , Geoffrey R. Oxnard , Khedoudja Nafa , Gregory J. Riely
Clinical Cancer Research 17 ( 5) 1169 -1180
421
2011
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
Geoffrey R. Oxnard , Maria E. Arcila , Camelia S. Sima , Gregory J. Riely
Clinical Cancer Research 17 ( 6) 1616 -1622
435
2011
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Yelena Y. Janjigian , Christopher G. Azzoli , Lee M. Krug , Leanne K. Pereira
Clinical Cancer Research 17 ( 8) 2521 -2527
110
2011
Phase II trial of bortezomib in KRAS G12D mutant lung cancers.
Anna Maria Litvak , Alexander E. Drilon , Natasha Rekhtman , Maria Catherine Pietanza
Journal of Clinical Oncology 33
10
2015
Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.
Maria E. Arcila , Helena Alexandra Yu , Alexander E. Drilon , Gregory J. Riely
Journal of Clinical Oncology 33
3
2015
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y Janjigian , Egbert F Smit , Harry JM Groen , Leora Horn
Cancer Discovery 4 ( 9) 1036 -1045
401
2014
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw , Dong-Wan Kim , Ranee Mehra , Daniel S.W. Tan
The New England Journal of Medicine 370 ( 13) 1189 -1197
1,711
2014
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw , Sai-Hong I. Ou , Yung-Jue Bang , D. Ross Camidge
The New England Journal of Medicine 371 ( 21) 1963 -1971
1,898
2014
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Nicolas Girard , Ronglai Shen , Tianhua Guo , Maureen F. Zakowski
Clinical Cancer Research 15 ( 22) 6790 -6799
185
2009
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Bruce E. Johnson , David M. Jackman , Vincent A. Miller , Leigh-Anne Cioffredi
Clinical Cancer Research 15 ( 16) 5267 -5273
487
2009
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Gregory J. Riely , Mark G. Kris , Binsheng Zhao , Tim Akhurst
Clinical Cancer Research 13 ( 17) 5150 -5155
340
2007
Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Gregory J. Riely , Vincent A. Miller
Clinical Cancer Research 13 ( 15)
53
2007
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
Thomas J Lynch , Philip D Bonomi , Charles Butts , Angela M Davies
Clinical Cancer Research 13 ( 15) 4583s -4588s
10
2007
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
James Bean , Gregory J. Riely , Marissa Balak , Jenifer L. Marks
Clinical Cancer Research 14 ( 22) 7519 -7525
217
2008
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J. Riely , Mark G. Kris , Daniel Rosenbaum , Jenifer Marks
Clinical Cancer Research 14 ( 18) 5731 -5734
657
2008
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa , Kim-Son H. Nguyen , Byoung C. Cho , Lecia V. Sequist
Clinical Cancer Research 14 ( 21) 7060 -7067
136
2008
Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer
Naiyer A. Rizvi , Gregory J. Riely , Christopher G. Azzoli , Vincent A. Miller
Journal of Clinical Oncology 26 ( 4) 639 -643
104
2008
Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Vincent A. Miller , Gregory J. Riely , Maureen F. Zakowski , Allan R. Li
Journal of Clinical Oncology 26 ( 9) 1472 -1478
265
2008
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
David Planchard , Julien Mazieres , Gregory J. Riely , Charles M. Rudin
Journal of Clinical Oncology 31 8009 -8009
143
2013